Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $207.50 short call and a strike $212.50 long call offers a potential 25.63% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $207.50 by expiration. The full premium credit of $1.02 would be kept by the premium seller. The risk of $3.98 would be incurred if the stock rose above the $212.50 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 22.33 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan Price Target Reduction; Lacing Up Nike: Doug Kass' Views
Mon, 02 Oct 2017 05:00:00 +0000
Doug Kass shares his thoughts on Allergan, Nike and a few other companies.
U.S. court strikes down Obama-era rule on tax inversions
Sat, 30 Sep 2017 03:10:10 +0000
A federal court in Texas on Friday ruled that the Obama administration acted unlawfully last year when its Treasury Department cracked down on U.S. companies that try to reduce their U.S. taxes by rebasing abroad, in a process known as inversion. The U.S. Chamber of Commerce and the Texas Association of Business had filed a lawsuit in Texas federal court that said a regulation from the Treasury Department in April 2016 exceeded what the law allows the department to do.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
Fri, 29 Sep 2017 13:20:01 +0000
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Tax reform could spark a wave of biopharma M&A
Thu, 28 Sep 2017 21:27:00 +0000
CNBC's Meg Tirrell discusses the failed attempts at Pfizer trying to acquire two companies in the past but how the Republican tax reform plan could change that. The “Fast Money” traders weigh in.
Will Conatus Liver Disease Candidate Drive Long-Term Growth?
Thu, 28 Sep 2017 13:23:01 +0000
Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.
Also on Market Tamer…
Follow Us on Facebook